Charles Ryan, MD | Authors

Articles

The Role of Abiraterone in Prostate Cancer

July 28, 2016

Charles J. Ryan, MD, professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, discusses the role of abiraterone acetate in the treatment of patients with prostate cancer, and the questions that remain about its use.

Dr. Charles Ryan on Abiraterone Acetate in Elderly mCRPC Patients

May 18, 2016

Charles Ryan, MD, Professor of Clinical Medicine and Urology, Department of Medicine, Program Leader, Genitourinary Medical Oncology at the Helen Diller Family Comprehensive Cancer at the Univeristy of California San Francisco, discusses abiraterone acetate in elderly chemotherapy naive patients with metastatic castration resistant prostate cancer (mCRPC).

Abiraterone and Enzalutamide for mCRPC

January 31, 2014

Charles Ryan, MD, Associate Clinical Professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the utility of abiraterone and enzalutamide for patients with metastatic castration-resistant prostate cancer.